Clinical trials: Neoplasms, Germ Cell and Embryonal
Recurrent Glioblastoma Multiforme(GBM)
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
- Trial name
- NCT05053880
- Testing
- ACT001, ACT001 + Pembrolizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Accendatech USA Inc.
BRAF V600 Mutation, Unresectable Melanoma
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation.
- Conditions
- BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
- Trial name
- NCT04759846
- Testing
- Encorafenib + Binimetinib
- Where
- 7 sites in Czechia, Italy and 1 more
- Sponsor
- Pierre Fabre Medicament
Glioma
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
This phase I, open-label, dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary…
- Trial name
- NCT02978261
- Testing
- PLB1001
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Melanoma
The Impact of Melanoma and Drug Treatment in the Real World
An observational, non-interventional registry study to collect real-world data from people living with melanoma and its treatment, which will be available to researchers to further the knowledge of melanoma and improve patient…
- Trial name
- NCT03379454
- Where
- United Kingdom
- Volunteers
- 819 people
- Sponsor
- Vitaccess Ltd
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected).
- Trial name
- NCT03655756
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- TuHURA Biosciences, Inc.
Melanoma
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
To evaluate the safety and tolerability of intradermal injections of IMM-101 (Heat-killed Mycobacterium obuense) in melanoma cancer patients.
- Trial name
- NCT01308762
- Testing
- Heat killed whole cell M. obuense (IMM-101) 0.1 mg, Heat-killed whole cell M.obuense (IMM-101) 0.5 mg, Heat killed whole cell M.obuense (IMM-101) 1.0 mg
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Immodulon Therapeutics Ltd
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Recurrent Diffuse Pontine Gliomas
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
This is a phase 2, single-arm, multi-center study, with a safety review component, designed to evaluate the efficacy and safety of nimotuzumab in approximately 44 patients with recurrent diffuse intrinsic pontine glioma (DIPG)…
- Trial name
- NCT00600054
- Testing
- nimotuzumab (anti EGFR humanized monoclonal antibody)
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- YM BioSciences
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Malignant Melanoma
Vaccine Therapy for Patients With Stage IV Melanoma
This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed.
- Trial name
- NCT00052156
- Testing
- CancerVax vaccine (CANVAXIN)
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 670 people
- Sponsor
- CancerVax Corporation
Glioblastoma Multiforme
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy.
- Trial name
- RESTORE (NCT03862430)
- Testing
- NanO2TM
- Where
- 12 sites in United States
- Volunteers
- 87 people
- Sponsor
- NuvOx LLC
High Grade Glioma
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With recurrent High Grade Glioma…
- Trial name
- NCT05362409
- Testing
- 5 Aminolevulinic Acid, CV01-delivered ultrasound
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alpheus Medical, Inc.
Melanoma
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
The study is designed as a multicenter, double blind, parallel-group, placebo-controlled, randomized, event driven Phase II study of DTIC with or without bosentan as first-line treatment in patients with stage IV melanoma.
- Trial name
- NCT01009177
- Testing
- Bosentan
- Where
- 12 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Actelion
Malignant Neoplasm
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with…
- Trial name
- NCT06894771
- Testing
- MK-4700, Pembrolizumab
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma
Ceritinib Rare Indications Study in ALK+ Tumors
This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration…
- Conditions
- Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor, Glioblastoma
- Trial name
- NCT02465528
- Testing
- Ceritinib (LDK378)
- Where
- 14 sites in Czechia, Denmark and 6 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma Multiforme
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
- Trial name
- NCT03382977
- Testing
- VBI-1901, Carmustine, Lomustine
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- VBI Vaccines Inc.
Metastatic Melanoma
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
The goal of the Phase 1 study was to find the recommended Phase 2 dose of the study drug IMO-2125 (tilsotolimod) that can be given in combination with ipilimumab (ipi) or pembrolizumab (pembro) to participants with metastatic…
- Trial name
- NCT02644967
- Testing
- IMO-2125, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Merkel Cell Carcinoma
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with MCC who have progressed on or after anti-PD-L1 therapy.
- Trial name
- NCT03167164
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Uveal Melanoma, Choroid Neoplasm
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal…
- Trial name
- NCT02771340
- Testing
- ICON-1
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Iconic Therapeutics, Inc.